Envisagenics, Inc., a New York-based biotechnology company leveraging artificial intelligence (AI) and RNA-splicing analytics for discovery and development of disease specific therapeutics, announced today...
Read More »Envisagenics wins SBIR grant for continued development of SpliceCore RNA-Seq analysis software
Envisagenics, Inc., a New York based biotechnology company, announced today that it was awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health (NIH). This grant will provide $1.5 million over two years for Envisagenics’ ...
Read More »Envisagenics named winner of Innovate.AI competition
Envisagenics is the developer of SpliceCore, software that analyzes RNA sequencing (RNA-seq) data to accelerate RNA therapeutics discovery using innovative machine learning to identify new...
Read More »Envisagenics closes $2.35M seed round and launches SpliceCore Platform for identifying RNA targets from splicing errors
Envisagenics, Inc., a biotechnology company that applies Artificial Intelligence to the genetic sequence of patients to discover new therapies, announced today that is has raised $2.35M in its seed round. The investors include Third Kind Venture Capital (3KVC), Cosine, LLC ...
Read More »Featured RNA-Seq Jobs – Bioinformatics
About Envisagenics Envisagenics is a bioinformatics startup developing cloud-based solutions to leverage biomedical big data and accelerate R&D therapeutics through machine learning. Envisagenics is a spin-off from Cold Spring Harbor Laboratory, a biomedical research institute ranked #1 worldwide for scientific impact ...
Read More »Breakout Labs Funds RNA-Seq Startup Envisagenics
Breakout Labs, the Thiel Foundation’s seed-stage fund for deep technology companies, announced its latest four investments, each propelling radical science and technology to improve human health. The new awards bring the total number of companies backed by Breakout Labs to ...
Read More »